Core Viewpoint - ST Tian Sheng (002872.SZ) announced that its wholly-owned subsidiary, Hubei Tian Sheng Pharmaceutical Co., Ltd., has received the approval notice from the National Medical Products Administration for its product "Sodium Bicarbonate Injection," which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval of "Sodium Bicarbonate Injection" indicates a significant milestone for the company in the pharmaceutical sector [1] - The consistency evaluation is crucial for generic drugs, ensuring they meet the same quality and efficacy standards as their branded counterparts [1]

一、药品基本情况 二、药品其他相关情况 证券代码：002872 证券简称：ST 天圣 公告编号：2025-056 天圣制药集团股份有限公司 关于全资子公司碳酸氢钠注射液通过仿制药 一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司（以下简称"公司"）之全资子公司湖北天圣药 业有限公司（以下简称"湖北天圣"）于近日收到国家药品监督管理局核准签发 的《药品补充申请批准通知书》，湖北天圣产品"碳酸氢钠注射液"通过仿制药 质量与疗效一致性评价（以下简称"一致性评价"）。现就相关事项公告如下： | 药品通用名称 | 碳酸氢钠注射液 | | | | --- | --- | --- | --- | | 剂型 | | 注射剂 注册分类 | 化学药品 | | 规格 | | 10ml：0.42g 原药品批准文号 | 国药准字 H42020420 | | 包装规格 | | 药品注册标准编号 5 支/盒 | YBH23982025 | | 申请内容 | | 新增申报规格 10ml:0.42g，同时申请仿制药质量和疗效一致性评 | | | | | ...

Core Viewpoint - ST Tian Sheng's subsidiary, Hubei Tian Sheng, has received approval from the National Medical Products Administration for its sodium bicarbonate injection, which has passed the consistency evaluation for generic drug quality and efficacy [1] Company Summary - The sodium bicarbonate injection is primarily used in clinical settings for the treatment of metabolic acidosis, alkalinizing urine, and as a non-specific treatment for certain drug overdoses through intravenous infusion [1]

Core Viewpoint - ST Tian Sheng has been penalized by the China Securities Regulatory Commission (CSRC) for inflating profits and failing to disclose related party transactions, resulting in a total fine of 4.99 million yuan [1][4]. Group 1: Financial Misconduct - ST Tian Sheng inflated its total profit by 92,204,254.47 yuan in 2017 and 28,823,001.51 yuan in 2018, which accounted for 30.21% and 20.61% of the reported profits for those years respectively [2]. - The company used off-balance sheet funds to pay sales expenses, leading to inflated profits of 174,783,429.59 yuan in 2017 and 47,908,869.95 yuan in 2018 [2]. - Additionally, ST Tian Sheng understated its profits by 82,579,175.12 yuan in 2017 and 19,085,868.44 yuan in 2018 through inflated procurement costs [2]. Group 2: Disclosure Failures - In 2017 and 2018, ST Tian Sheng failed to disclose related party transactions amounting to 481,025,946.65 yuan and 48,631,061.00 yuan, which represented 15.08% and 1.49% of the net assets at the end of those periods [3]. - The undisclosed related party transactions included 328,521,817.60 yuan that exceeded 15% of the latest audited net assets, violating disclosure regulations [3]. Group 3: Regulatory Actions - The CSRC has issued a warning and imposed a fine of 60,000 yuan for the failure to disclose related party transactions and for the false records in the annual reports [4]. - The former chairman Liu Qun has been fined 90,000 yuan and banned from the market for life due to his role in directing these illegal activities [4]. - Following these actions, ST Tian Sheng's stock will be subject to additional risk warnings, maintaining its designation as "ST Tian Sheng" with a trading code of 002872 [4].

Group 1 - The company ST Tian Sheng (002872.SZ) received an administrative penalty notice from the China Securities Regulatory Commission on September 12, 2025, indicating that the financial indicators in its annual report contained false records [1] - The notice states that the company violated Article 9.8.1, Item 8 of the Shenzhen Stock Exchange Listing Rules, which will result in additional risk warnings for its stock [1] - Following the additional risk warning, the stock will continue to be traded under the name "ST Tian Sheng" with the same stock code 002872, and the daily price fluctuation limit remains at 5% [1]

格隆汇9月12日丨ST天圣(002872.SZ)公布，公司于2025年9月12日收到中国证券监督管理委员会重庆监 管局出具的《行政处罚事先告知书》，根据本次《行政处罚事先告知书》认定的情况，公司披露的年度 报告财务指标存在虚假记载，触及《深圳证券交易所股票上市规则》第9.8.1条第八项的情形，公司股票 将被叠加实施其他风险警示。本次被叠加实施其他风险警示后，股票简称仍为"ST天圣"，股票代码仍 为002872，股票交易的日涨跌幅限制仍为5%。本次叠加其他风险警示，公司股票不停牌。 ...

Core Viewpoint - ST Tian Sheng (002872) has received an administrative penalty notice from the Chongqing Securities Regulatory Bureau for information disclosure violations linked to the criminal activities of its actual controller, Liu Qun, highlighting the capital market's "zero tolerance" regulatory stance [1][2] Summary by Sections Case Background - ST Tian Sheng inflated its total profits by 92 million yuan and 28 million yuan in 2017 and 2018, respectively, through off-balance-sheet funding pools to pay sales expenses, corresponding to 30.21% and 20.61% of the disclosed profits for those periods [1] Regulatory Actions - The Chongqing Securities Regulatory Bureau imposed a total fine of 4.39 million yuan on ST Tian Sheng and 22 responsible individuals, with Liu Qun receiving a lifetime market ban and two other individuals facing market bans of 5 and 8 years [1] - The regulatory body emphasized accountability for both executive and non-executive personnel involved in the violations, reinforcing the principle that "leaving office does not exempt from responsibility" [1] Broader Implications - The case demonstrates a "multi-dimensional accountability" approach in regulation, with the Chongqing Securities Regulatory Bureau quickly initiating administrative investigations following Liu Qun's criminal conviction for misappropriating company funds, thereby establishing a closed loop of criminal and administrative accountability [2] - Following the penalty decision, regulatory authorities will coordinate with investor service centers and financial courts to facilitate civil compensation claims for eligible investors [2] - Market participants view this case as both a warning and a reassurance, emphasizing the importance of transparency in information disclosure and the ongoing enhancement of investor protection mechanisms [2]

证券代码：002872 证券简称：ST 天圣 公告编号：2025-055 天圣制药集团股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会决议的情形。 一、会议召开的基本情况 1、会议召开时间 （1）现场会议时间：2025 年 9 月 12 日（星期五）下午 14：00 开始。 1 参加本次股东大会现场会议和网络投票的股东（包括股东代理人）共计 100 名，代表有表决权的股份数量 113,225,082 股，占公司有表决权股份总数的 35.6054%。其中： （1）出席现场会议的股东（包括股东代理人）共 6 名，代表有表决权的股 份为 105,331,411 股，占公司有表决权股份总数的 33.1231%。 （2）网络投票时间：其中，通过深圳证券交易所交易系统进行网络投票的 具体时间为：2025 年 9 月 12 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳 证券交易所互联网投票系统投 ...

特别提示： 1、因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易 所股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司" 或"天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 2、公司于 2025 年 9 月 12 日收到中国证券监督管理委员会重庆监管局（以 下简称"重庆证监局"）出具的《行政处罚事先告知书》（处罚字（2025）4 号），根据本次《行政处罚事先告知书》认定的情况，公司披露的年度报告财 务指标存在虚假记载，触及《深圳证券交易所股票上市规则》第 9.8.1 条第八项 的情形，公司股票将被叠加实施其他风险警示。 本次被叠加实施其他风险警示后，股票简称仍为"ST 天圣"，股票代码仍 为 002872，股票交易的日涨跌幅限制仍为 5%。本次叠加其他风险警示，公司 股票不停牌。 一、股票的种类、简称、股票代码、被叠加实施其他风险警示的起始日以 及日涨跌幅限制 1、股票种类仍为人民币普通股； 证券代码：002872 证券简称：ST 天圣 公告编号：2025-058 天圣制药集团股份有限公司 关于公司股票交易被叠加实施其他风险警示的公告 本公司及董事会全体 ...

层 地址：北京市朝阳区光华路正大中心北塔 11-12 邮编：100020 电话：010-65876666 传真：010-65876666-6 北京中银律师事务所 关于天圣制药集团股份有限公司 2025 年第三次临时股东大会之 法律意见书 二〇二五年九月 法律意见书 关于天圣制药集团股份有限公司 2025 年第三次临时股东大会之 法律意见书 致：天圣制药集团股份有限公司 北京中银律师事务所（以下简称"本所"）接受天圣制药集团股份有限公司 （以下简称"公司"）的委托，指派见证律师出席公司 2025 年第三次临时股东大 会（以下简称"本次股东大会"）进行法律见证，并依据《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《上市公司治理准则》 （以下简称"《治理准则》"）等法律、法规和规范性文件以及《天圣制药集团股 份有限公司章程》（以下简称"《公司章程》"）的规定就公司本次股东大会的召 集、召开程序、出席会议人员的资格、表决程序、表决结果等有关事宜出具法律 意见书。 本所及本所律师依据《证券法》《律师事务所 ...